Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012

For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.

After 12 weeks, the researchers found that the placebo-subtracted decrease in hemoglobin A1c was a significant −0.44 percent with metformin-imeglimin. Compared with metformin-placebo, metformin-imeglimin correlated with significant improvements in fasting plasma glucose and the proinsulin/insulin ratio from baseline. The safety profile of the metformin-imeglimin combination was similar to that of metformin-placebo, and the combination was generally well tolerated.

"This phase II study demonstrated that first-in-class imeglimin was well tolerated and effective when combined with metformin as a potential new treatment for type 2 diabetes," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Poxel, which primarily funded the study and manufactures imeglimin.

Related Stories

Although the drug metformin is considered the gold standard in the management of type 2 diabetes, a study by a group of French researchers published in this week's PLoS Medicine suggests that the long-term benefits of this ...

(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects are observed according ...

A commonly prescribed diabetes drug, metformin, reduces the overall cancer risk in people with Type 2 diabetes, a large systematic review study finds. The results to be presented at The Endocrine Society's 94th Annual Meeting ...

(HealthDay) -- Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue ...

(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Metformin therapy has a beneficial treatment effect over placebo in improving body mass index (BMI) and fasting glucose levels in obese children, according to a recent study accepted for publication in The Endocrine Society's ...

Recommended for you

More and more Americans on-the-go are skipping the "most important meal of the day," not eating until lunch. This tendency to miss breakfast has already been linked to the growing epidemic of obesity and cardiovascular problems ...

New research from Harvard T.H. Chan School of Public Health describes a molecular mechanism that helps explain how obesity-related inflammation can lead to type 2 diabetes. The findings describe a surprising connection between ...

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports, reveals that administration ...

For nearly a century, insulin has been a life-saving diabetes treatment. Now scientists are testing a tantalizing question: What if pills containing the same medicine patients inject every day could also prevent the disease?

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological Sciences, that crosstalk ...

0 comments

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.